Abstract
To determine cut-off value of dynamic contrast-enhanced (DCE) magnetic resonance imaging
(MRI) parameters for differentiation of prostate malignant from benign and cancer
with high-grade Gleason score (GS) (GS>7) from low-grade GS (GS≤7), 35 patients (24
malignant and 11 benign) who underwent DCE-MRI were included. Difference between malignant
and benign was statistically significant for all magnetic resonance parameters except
Ve. The cut-off values were Ktrans=0.184 min−1, Kep=0.695 min−1, iAUC=4.219 mmol/l/min, and ADC=1340.5 mm2/s. A significant difference in mean values of Ktrans and Kep between cancer with high-grade GS and low-grade GS was also observed. Ktrans and Kep showed a significant correlation with GS.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global patterns of cancer incidence and mortality rates and trends.Cancer Epidemiol Biomarkers Prev. 2010; 19: 1893-1907
- Prostate cancer magnetic resonance imaging (MRI): multidisciplinary standpoint.Quant Imaging Med Surg. 2013; 3: 100-112
- Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens.Scand J Urol Nephrol Suppl. 2005; 34–63
- Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer.J Magn Reson Imaging. 2012; 36: 912-919
- Advancements in MR imaging of the prostate: from diagnosis to interventions.Radiographics. 2011; 31: 677-703
- Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter.N Engl J Med. 2004; 350: 2239-2246
- Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.AJR Am J Roentgenol. 2012; 198: 1277-1288
- Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols.J Magn Reson Imaging. 1999; 10: 223-232
- Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma.Br J Radiol. 2003; 76: 153-162
- Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.Magn Reson Med. 2006; 56: 993-1000
- Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis—correlation with biopsy and histopathology.J Magn Reson Imaging. 2006; 24: 108-113
- Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3 T—quantitative correlation with biopsy.Magn Reson Imaging. 2010; 28: 621-628
- Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.AJR Am J Roentgenol. 2007; 189: 849
- Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA.Clin Radiol. 2000; 55: 99-109
- Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI.Magn Reson Med. 2005; 53: 249-255
- Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.J Magn Reson Imaging. 2004; 20: 279-287
- Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.J Magn Reson Imaging. 2009; 30: 327-334
- Assessment of extravascular extracellular space fraction in human melanoma xenografts by DCE-MRI and kinetic modeling.Magn Reson Imaging. 2008; 26: 160-170
- Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla.Invest Radiol. 2009; 44: 572-576
- Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.AJR Am J Roentgenol. 2011; 197: 1382-1390
- Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.Invest Radiol. 2012; 47: 624-633
- Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score—a computer-aided diagnosis development study.Radiology. 2013; 267: 787-796
- Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps.AJR Am J Roentgenol. 2011; 197: 1122-1129
- Average arterial input function for quantitative dynamic contrast enhanced magnetic resonance imaging of neck nodal metastases.BMC Med Phys. 2009; 9: 4
- Analysis of DCE-MRI for diagnosis and neoadjuvantchemotherapy monitoring of breast cancer.J Magn Reson Imaging. 2012; 3: 235-247
- Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report.Cancer Res. 2005; 65: 7041-7044
- Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer.Pol J Pathol. 2013; 64: 33-38
- Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays.Hum Pathol. 2013; 44: 495-502
- Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database.Urology. 2007; 70: 277-282
- Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings.Am J Surg Pathol. 1997; 21: 566-576
Article info
Publication history
Published online: May 07, 2015
Accepted:
April 28,
2015
Received in revised form:
April 16,
2015
Received:
December 12,
2014
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
